PerformanceMedium Risk

Mod GRF 1-29

Also known as: CJC-1295 no DAC, Modified GRF 1-29, Tetrasubstituted GRF 1-29

Half-life:: ~30 minutes

Administration Routes

subcutaneous injection

PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Modified GHRH analog; binds GHRH receptors with improved stability to produce physiological GH pulses when combined with a GHRP

A stabilized GHRH analog that amplifies natural GH pulses. Most effective when combined with a GHRP (e.g., Ipamorelin or GHRP-6) for synergistic GH release.

Primary Research Areas

GH pulse amplification
muscle growth
fat metabolism
recovery

Risk Profile

Medium Risk

Moderate risk profile in research contexts. Consult a healthcare professional before use.

Regulatory Status

Research OnlyNot Evaluated by FDA

GHRH analog (CJC-1295 without DAC). Related to sermorelin but structurally distinct (tetrasubstituted AAs). No FDA approval. Not on FDA 503A bulks list. WADA prohibited. Research chemical.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Where to Find Mod GRF 1-29

No active associated providers listed yet.